Sarepta Therapeutics Inc. (DE) (SRPT)
$22.99
$-0.22
(-0.95%)
As on 03-Sep-2026 16:19EDT
Market cap
$2,203 Mln
Revenue (TTM)
$1,974 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
16.9
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$-1.8
-
Face value
--
-
Shares outstanding
105,627,021
10 Years Aggregate
CFO
$-2,762.99 Mln
EBITDA
$-3,340.74 Mln
Net Profit
$-3,963.14 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
| 6.8 | 54.7 | 41.5 | 26.6 | -42.7 | -22.0 | -1.6 |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
| -82.3 | 25.9 | -25.6 | 43.9 | -47.2 | 32.1 | 18.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
|
23.0 | 2,203.4 | 1,974.3 | -136.7 | -3.0 | -10.2 | -- | 1.5 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Sarepta Therapeutics Inc. (DE) (SRPT)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare... diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Mr. Douglas S. Ingram Esq.
-
President, CEO & Director
Mr. Douglas S. Ingram Esq.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sarepta Therapeutics Inc. (DE) (SRPT)
What is the current share price of Sarepta Therapeutics Inc (DE) (SRPT) Today?
The share price of Sarepta Therapeutics Inc (DE) (SRPT) is $22.99 (NASDAQ) as of 03-Sep-2026 16:19 EDT. Sarepta Therapeutics Inc (DE) (SRPT) has given a return of -42.75% in the last 3 years.
What is the current PB & PE ratio of Sarepta Therapeutics Inc (DE) (SRPT)?
Since, TTM earnings of Sarepta Therapeutics Inc (DE) (SRPT) is negative, P/E ratio is not available.
The P/B ratio of Sarepta Therapeutics Inc (DE) (SRPT) is 1.49 times as on 28-Aug-2026, a 71 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.16 |
1.98 |
2024 |
56.07 |
8.63 |
2023 |
-19.00 |
11.85 |
2022 |
-16.18 |
29.57 |
2021 |
-17.18 |
7.75 |
What is the 52 Week High and Low of Sarepta Therapeutics Inc (DE) (SRPT)?
The 52-week high and low of Sarepta Therapeutics Inc (DE) (SRPT) are Rs 25.32 and Rs 14.69 as of 04-Sep-2026.
What is the market cap of Sarepta Therapeutics Inc (DE) (SRPT)?
Sarepta Therapeutics Inc (DE) (SRPT) has a market capitalisation of $ 2,203 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sarepta Therapeutics Inc (DE) (SRPT)?
Before investing in Sarepta Therapeutics Inc (DE) (SRPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.